参考文献/References:
[1] TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2] 唐志柳,白洁,顾丽娜,等.2000~2010年我国前列腺癌和乳腺癌流行状况的系统性综述[J].中国肿瘤,2013,22 (4):260-265.
[3] BERNS A,BREUER M,VERBEEK S,et al.Transgenic mice as a means to study synergism between oncogenes[J].Int J Cancer Suppl,1989,4:22-25.
[4] XU J,ZHANG T,WANG T,et al.PIM kinases:an overview in tumors and recent advances in pancreatic cancer[J].Future Oncol,2014,10(5):865-876.
[5] NARLIK-GRASSOW M,BLANCO-APARICIO C,CECILIA Y,et al.Conditional transgenic expression of Pim-1 kinase in prostate induces inflammation-dependent neoplasia[J].PLoS One,2013,8(4):e60277.
[6] AGUIRRE E,RENNER O,NARLIK-GRASSOW M,et al.Genetic modeling of PIM proteins in cancer:proviral tagging and cooperation with oncogenes,tumor suppressor genes,and carcinogens[J].Front Oncol,2014,4:109.
[7] LEUNG C O,WONG C C,FAN D N,et al.PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma[J].Oncotarget,2015,6(13):10880-10892.
[8] LIU H T,WANG N,WANG X,et al.Overexpression of Pim-1 is associated with poor prognosis in patients with esophageal squamous cell carcinoma[J].J Surg Oncol,2010,102(6):683-688.
[9] WARNECK-EBERZ U,BOLLSCHWEILER E,DREBBER U,et al.Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer[J].Anticancer Res,2009,29(11):4451-4455.
[10] WARNECKE-EBERZ U,BOLLSCHWEILER E,DREBBER U,et al.Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases[J].Oncol Rep,2008,20(3):619-624.
[11] 陆平,李云鹏,张万峰,等.PIM-1蛋白激酶在乳腺癌组织中的表达及意义[J].中国医师杂志,2012,14(6):727.
[12] ROH M,FRANCO O E,HAYWARD S W,et al.A role for polyploidy in the tumorigenicity of Pim-1-expressing human prostate and mammary epithelial cells[J].PLoS One,2008,3(7):e2572.
[13] NATARAJAN K,BHULLAR J,SHUKLA S,et al.The Pim kinase inhibitor SGI-1776 decreases cell surface expression of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and drug transport by Pim-1-dependent and-independent mechanisms[J].Biochem Pharmacol,2013,85(4):514-524.
[14] MOODY S E,SCHINZEL A C,SINGH S,et al.PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling[J].Oncogene,2015,34(16):2061-2071.
[15] JIMENEZ-GARCIA M P,LUCENA-CACACE A,ROBLES-FRIAS MJ,et al.Inflammation and stem markers association to PIM1/PIM2 kinase-induced tumors in breast and uterus[J].Oncotarget,2017,8(35):58872-58886.
[16] HORIUCHI D,CAMARDA R,ZHOU A Y,et al.PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression[J].Nat Med,2016,22(11):1321-1329.
[17] ZHAO W,QIU R,LI P,et al.PIM1:a promising target in patients with triple-negative breast cancer[J].Med Oncol,2017,34(8):142.
[18] ZHANG G,LIU Z,CUI G,et al.MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells[J].Tumour Biol,2014,35(11):11137-11145.
[19] MALINEN M,JAASKELAINEN T,PELKONEN M,et al.Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors[J].Mol Cell Endocrinol,2013,365(2):270-276.
[20] BELLON M,LU L,NICOT C,et al.Constitutive activation of Pim-1 kinase is a therapeutic target for adult T-cell leukemia[J].Blood,2016,127(20):2439-2450.
[21] BLANCO-APARICIO C,CAMERO A.Pim kinases in cancer:diagnostic,prognostic and treatment opportunities[J].Biochem Pharmacol,2013,85(5):629-643.
[22] SANTIO N M,LANDOR S K,VAHTERA L,et al.Phosphorylation of Notch1 by Pim kinases promotes oncogenic signaling in breast and prostate cancer cells[J].Oncotarget,2016,7(28):43220-43238.
[23] HORIUCHI D,CAMARDA R,ZHOU A Y,et al.PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression[J].Nat Med,2016,22(11):1321-1329.
[24] 郑小洲,金晓磊,赵临襄.小分子PIM激酶抑制剂的研究进展[J].中国药物化学杂志,2013,23(6):499-505.
相似文献/References:
[1]陈建丽,胡新荣.p16在肿瘤中的表达与人乳头瘤病毒感染的关系[J].新乡医学院学报,,():000.
[2]张明彩 贾红霞 赵卫星 秦志强 付佶.乳腺浸润性导管癌冰冻与石蜡切片细胞核的形态计量对比研究[J].新乡医学院学报,1999,16(02):110.
[3]周文科 综述 张新中 审校.岩斜区侧方手术入路的研究进展[J].新乡医学院学报,2000,17(06):470.
[4]于维霞,王玉红 郭悦鹏,杜荣,等.T细胞亚群测定鉴别结核性与癌性胸腔积液[J].新乡医学院学报,2000,17(01):032.
[5]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[6]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[7]刘 薇.妇科肿瘤25例动脉插管化疗的观察与护理[J].新乡医学院学报,2003,20(03):003.
[8]刘薇.妇科肿瘤25例动脉插管化疗的观察与护理[J].新乡医学院学报,2003,20(03):001.
[9]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[10]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.